These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 27773592)
21. Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations. Vermeulen F; Le Camus C; Davies JC; Bilton D; Milenković D; De Boeck K J Cyst Fibros; 2017 Jan; 16(1):36-40. PubMed ID: 26996268 [TBL] [Abstract][Full Text] [Related]
22. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). Rosenfeld M; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Chilvers M; Higgins M; Tian S; Cooke J; Davies JC; J Cyst Fibros; 2019 Nov; 18(6):838-843. PubMed ID: 31053538 [TBL] [Abstract][Full Text] [Related]
23. GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). van Koningsbruggen-Rietschel S; Conrath K; Fischer R; Sutharsan S; Kempa A; Gleiber W; Schwarz C; Hector A; Van Osselaer N; Pano A; Corveleyn S; Bwirire D; Santermans E; Muller K; Bellaire S; Van de Steen O J Cyst Fibros; 2020 Mar; 19(2):292-298. PubMed ID: 31594690 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M; Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913 [TBL] [Abstract][Full Text] [Related]
25. Changes of CFTR functional measurements and clinical improvements in cystic fibrosis patients with non p.Gly551Asp gating mutations treated with ivacaftor. Mesbahi M; Shteinberg M; Wilschanski M; Hatton A; Nguyen-Khoa T; Friedman H; Cohen M; Escabasse V; Le Bourgeois M; Lucidi V; Sermet-Gaudelus I; Bassinet L; Livnat G J Cyst Fibros; 2017 Jan; 16(1):45-48. PubMed ID: 27659740 [TBL] [Abstract][Full Text] [Related]
26. Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study. Nick JA; St Clair C; Jones MC; Lan L; Higgins M; J Cyst Fibros; 2020 Jan; 19(1):91-98. PubMed ID: 31784217 [TBL] [Abstract][Full Text] [Related]
27. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Flume PA; Liou TG; Borowitz DS; Li H; Yen K; Ordoñez CL; Geller DE; Chest; 2012 Sep; 142(3):718-724. PubMed ID: 22383668 [TBL] [Abstract][Full Text] [Related]
28. CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. Bell SC; Barry PJ; De Boeck K; Drevinek P; Elborn JS; Plant BJ; Minić P; Van Braeckel E; Verhulst S; Muller K; Kanters D; Bellaire S; de Kock H; Geller DE; Conrath K; Van de Steen O; van der Ent K J Cyst Fibros; 2019 Sep; 18(5):700-707. PubMed ID: 31056441 [TBL] [Abstract][Full Text] [Related]
36. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Davies JC; Wainwright CE; Sawicki GS; Higgins MN; Campbell D; Harris C; Panorchan P; Haseltine E; Tian S; Rosenfeld M Am J Respir Crit Care Med; 2021 Mar; 203(5):585-593. PubMed ID: 33023304 [No Abstract] [Full Text] [Related]
37. Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition. Peleg AY; Choo JM; Langan KM; Edgeworth D; Keating D; Wilson J; Rogers GB; Kotsimbos T J Cyst Fibros; 2018 Jan; 17(1):50-56. PubMed ID: 29042177 [TBL] [Abstract][Full Text] [Related]
38. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation. Guimbellot JS; Baines A; Paynter A; Heltshe SL; VanDalfsen J; Jain M; Rowe SM; Sagel SD; J Cyst Fibros; 2021 Mar; 20(2):213-219. PubMed ID: 33249004 [TBL] [Abstract][Full Text] [Related]
39. Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation. Berkers G; van der Meer R; van Mourik P; Vonk AM; Kruisselbrink E; Suen SW; Heijerman HG; Majoor CJ; Koppelman GH; Roukema J; Janssens HM; de Rijke YB; Kemper EM; Beekman JM; van der Ent CK; de Jonge HR J Cyst Fibros; 2020 Nov; 19(6):955-961. PubMed ID: 32499204 [TBL] [Abstract][Full Text] [Related]